The text starts here.

Products

Our Products

Eisai positions “dementia-related and neurological diseases (neurology)” and “cancer (oncology)” as two strategically important areas where we can find out “Ricchi”, areas where patients true needs remain unmet and we can become a front-runner. Accordingly, the Neurology Business Group and the Oncology Business Group were established as organizational structures that aggregate all functions from research and development through to sales.

Eisai is striving to implement initiatives that will bring about growth for our four global brands Halaven®, Lenvima®, Fycompa®, and BELVIQ®, based on programs to maximize their value which includes additional and expanded indications.

In neurology, our in-house discovered and developed antiepileptic drug Fycompa® is available in Europe, the Americas and Asia, and was launched in Japan in May 2016. Aricept® was first launched in January 1997 in the United States and is now approved and marketed in more than 90 countries worldwide. Moreover, as a leading pharmaceutical company in the development of dementia treatments, we are also expanding our educational activities that promote the early diagnosis and early treatment of dementia. In Japan, Aricept® was approved for the treatment of dementia with Lewy bodies in September 2014.

In oncology, Halaven®, a novel anticancer agent discovered and developed in-house, has been launched in Japan, the United States, Europe and Asia. Lenvima®, another anticancer agent discovered and developed in-house, was launched in the United States, Japan and in Europe in 2015, and in South Korea in February 2016.

(Information current as of June 2016)

Major Products

  Sales Regions
Four Global Brands
  Halaven (anticancer agent)
  Lenvima (anticancer agent)
  Fycompa (antiepileptic agent)
  BELVIQ (antiobesity agent)
 
Japan, Americas, Europe, Asia
Japan, Americas, Europe, Asia
Japan, Americas, Europe, Asia
US
Pariet/AcipHex (proton-pump inhibitor) Japan, US, Europe, China, Asia
Aricept (treatment for Alzheimer's disease / dementia with Lewy bodies) Japan, Americas, Europe, China, Asia
Humira (fully human anti-TNF-α monoclonal antibody) Japan, South Korea, Taiwan

* Pariet is marketed in Japan by EA Pharma.

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan and the Philippines.

(Information current as of June 2016)

Major Products by Region

Japan Prescription Pharmaceuticals
Humira (fully human anti-TNF-α monoclonal antibody)
Aricept (treatment for Alzheimer's disease / dementia with Lewy bodies)
Pariet (proton-pump inhibitor)*
Methycobal (peripheral neuropathy treatment)
Lunesta (insomnia treatment)
Halaven (anticancer agent)
Warfarin (oral anticoagulant)
Elental (branched-chain amino acid preparation)*
Livact (osteoporosis treatment)*
Actonel (osteoporosis treatment)
Consumer Healthcare (Over-the-Counter) Products
Chocola BB group (including Vitamin B2 preparation Chocola BB Plus)
Americas** Aloxi (antiemetic agent)
Halaven (anticancer agent)
Banzel (antiepileptic agent)
AcipHex (proton-pump inhibitor)
Lenvima (anticancer agent)
BELVIQ (antiobesity agent)
Fycompa (antiepileptic agent)
China Methycobal (peripheral neuropathy treatment)
Stronger Neo-Minophagen C / Glycyron tablets (liver disease / allergic disease treatment)
Aricept (treatment for Alzheimer's disease)
Pariet (proton-pump inhibitor)
Asia Aricept (treatment for Alzheimer's disease)
Humira (fully human anti-TNF-α monoclonal antibody)
Pariet (proton-pump inhibitor)
Methycobal (peripheral neuropathy treatment)
Halaven (anticancer agent)
Europe Halaven (anticancer agent)
Zonegran (antiepileptic agent)
Zebinix (antiepileptic agent)
Fycompa (antiepileptic agent)
Inovelon (antiepileptic agent)
Lenvima (anticancer agent)

*  Marketed by EA Pharma.

** The U.S. is the only country in the Americas where Eisai markets AcipHex and BELVIQ.

(Information current as of June 2016)

Related Links